Pharvaris (PHVS) has released an update.
Pharvaris, a biopharmaceutical company, showcased promising data on deucrictibant, an oral treatment for hereditary angioedema (HAE), noting substantial symptom resolution in 78.6% of participants within 24 hours and higher treatment satisfaction compared to placebo. The company aims to position deucrictibant as a leading therapy for HAE, with ongoing studies to further establish its long-term safety and efficacy. Pharvaris’ reports from recent congresses suggest deucrictibant’s potential as both an on-demand and prophylactic treatment, highlighting its effectiveness and convenience.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
